Now showing items 1-3 of 3

    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11)
      BACKGROUND:Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. 

      Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, J-J; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators (2017-11)
      BACKGROUND:Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ...
    • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. 

      Curigliano, G; Burstein, HJ; Winer, EP; Gnant, M; Dubsky, P; Loibl, S; Colleoni, M; Regan, MM; Piccart-Gebhart, M; Senn, H-J; Thürlimann, B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, SY; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J; Denkert, C; Di Leo, A; Ejlertsen, B; Francis, P; Galimberti, V; Garber, J; Gulluoglu, B; Goodwin, P; Harbeck, N; Hayes, DF; Huang, C-S; Huober, J; Hussein, K; Jassem, J; Jiang, Z; Karlsson, P; Morrow, M; Orecchia, R; Osborne, KC; Pagani, O; Partridge, AH; Pritchard, K; Ro, J; Rutgers, EJT; Sedlmayer, F; Semiglazov, V; Shao, Z; Smith, I; Toi, M; Tutt, A; Viale, G; Watanabe, T; Whelan, TJ; Xu, B (2017-08)
      The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of ...